Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Pfizer Inc.

PFE

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

Last trade $28.44
Day change -$0.42 (-1.46%)
Day range $28.38 – $28.86
Volume 16,415,838
Market cap $164.50B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$164.5B
Price / earnings
40.79×
Price / book
1.85×
Price / sales
2.59×
EV / sales
3.54×
EV / EBITDA
9.75×

Profitability

Earnings per share
$0.71
Return on assets
1.97%
Return on equity
4.53%
Dividend yield
5.95%

Liquidity and leverage

Debt / equity
0.7×
Current ratio
1.42×
Quick ratio
1.1×
Cash ratio
0.06×

Cash flow

Price / cash flow
11.61×
Price / free cash flow
13.96×
Free cash flow
$11.79B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PFE, quarterly periods
Line itemQ3 FY2026 Sep 27, 2026Q2 FY2026 Jun 28, 2026Q1 FY2026 Mar 29, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 28, 2025Q2 FY2025 Jun 29, 2025Q1 FY2025 Mar 30, 2025Q4 FY2024 Dec 31, 2024
Revenue$16.58B$15.03B$14.45B$17.56B$16.65B$14.65B$13.72B$17.76B
Cost of revenue$4.03B$4.09B$3.55B$5.27B$4.17B$3.78B$2.85B$5.91B
Gross profit$12.56B$10.94B$10.9B$12.29B$12.48B$10.88B$10.87B$11.86B
Selling, general and administrative$3.28B$3.41B$2.96B$4.16B$3.19B$3.42B$3.03B$4.27B
Research and development$3.02B$2.81B$2.49B$3.21B$2.55B$2.48B$2.2B$3.04B
Total operating expenses$8.88B$7.88B$6.87B$9.42B$8.63B$7.09B$7.13B$9.51B
Operating income$3.67B$3.06B$4.03B$2.87B$3.85B$3.78B$3.74B$2.35B
Interest expense-$662M-$667M$0$0-$652M-$654M$0$0
Income before taxes$3.39B-$653M$3.17B-$1.64B$3.33B$3.04B$2.79B-$10M
Income taxes$134M-$407M$461M-$2M-$216M$141M-$189M-$421M
Net income$3.25B-$238M$2.7B-$1.64B$3.55B$2.93B$2.97B$418M
Net income attributable to common shareholders$3.24B-$248M$2.69B-$1.65B$3.54B$2.91B$2.97B$410M
EBITDA$6.71B$5.16B$5.88B$5.37B$7.19B$5.39B$6.04B$4.98B
Basic earnings per share$0.57-$0.04$0.47-$0.29$0.62$0.51$0.52$0.07
Diluted earnings per share$0.56-$0.04$0.47-$0.29$0.62$0.51$0.52$0.07

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

Zacks Investment Research

Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?

The iShares Select Dividend ETF (DVY) is a passively managed fund with $23.65 billion in assets offering exposure to large-cap value stocks. With a 0.38% expense ratio, 3.29% dividend yield, and 17.8% year-to-date return, it presents a medium-risk option for dividend-focused investors. However, alternatives like SCHD and VTV offer lower expense ratios, earning DVY a Zacks ETF Rank of 3 (Hold).

The Motley Fool

2 Stocks With Dividend Yields of 4% or More to Buy in November

The article recommends Pfizer and PepsiCo as overlooked dividend stocks offering yields above 4% in a market focused on AI and growth. Pfizer is diversifying into oncology with strong acquisition-driven growth, while PepsiCo is recovering from weight-loss drug concerns through international expansion and pricing power. Both stocks offer durability and reliable dividend income for long-term investors.

GlobeNewswire Inc.

Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035

The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and projected to reach USD 64.96 billion by 2035 at a 24.71% CAGR. Eli Lilly and Novo Nordisk dominate with strong Q3 2026 results, while Pfizer, Roche, and Amgen are investing billions to compete. Key trends include oral GLP-1 formulations, higher efficacy rates (>20% weight loss), and significant manufacturing capacity investments.

Zacks Investment Research

The Zacks Analyst Blog Highlights Visa, ExxonMobil Holdings and Pfizer

Zacks analysts reviewed three major stocks on November 16, 2026. Visa benefits from strong brand and digital transaction growth but faces profitability pressures from rising expenses. ExxonMobil gains from low-cost production and expansion opportunities but remains exposed to commodity volatility. Pfizer struggles with patent expirations and subdued near-term growth, though pipeline investments in oncology and obesity offer longer-term potential.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Nov 6, 2026$0.43Dec 7, 2026recurring
Jul 24, 2026$0.43Sep 1, 2026recurring
May 8, 2026$0.43Jun 12, 2026recurring
Jan 23, 2026$0.43Mar 6, 2026recurring
Nov 7, 2025$0.43Dec 1, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.